Published in J Pharmacol Exp Ther on November 04, 2004
The nociceptive and anti-nociceptive effects of bee venom injection and therapy: a double-edged sword. Prog Neurobiol (2010) 1.23
Effect of buspirone on thermal sensory and pain thresholds in human volunteers. BMC Clin Pharmacol (2009) 0.85
In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat. Psychopharmacology (Berl) (2011) 0.78
The regulation of sGC on the rat model of neuropathic pain is mediated by 5-HT1ARs and NO/cGMP pathway. Am J Transl Res (2016) 0.77
5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception. Br J Pharmacol (2009) 0.77
[(3)H]-F13640, a novel, selective and high-efficacy serotonin 5-HT(1A) receptor agonist radioligand. Naunyn Schmiedebergs Arch Pharmacol (2010) 0.77
For the love of paradox: from neurobiology to pharmacology. Behav Pharmacol (2011) 0.75
Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther (2002) 1.87
Noradrenergic mechanisms in neurodegenerative diseases: a theory. Brain Res Brain Res Rev (2004) 1.63
WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Eur J Neurosci (2009) 1.42
Behavioral analyses of GHB: receptor mechanisms. Pharmacol Ther (2008) 1.31
Decynium-22 enhances SSRI-induced antidepressant-like effects in mice: uncovering novel targets to treat depression. J Neurosci (2013) 1.29
Organic cation transporter 3: Keeping the brake on extracellular serotonin in serotonin-transporter-deficient mice. Proc Natl Acad Sci U S A (2008) 1.29
PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol (2002) 1.22
Feeding conditions differentially affect the neurochemical and behavioral effects of dopaminergic drugs in male rats. Eur J Pharmacol (2008) 1.18
Effects of fluvoxamine on a multiple schedule of ethanol- and food-maintained behavior in two rat strains. Psychopharmacology (Berl) (2005) 1.10
Differences in the relative potency of SR 141716A and AM 251 as antagonists of various in vivo effects of cannabinoid agonists in C57BL/6J mice. Eur J Pharmacol (2007) 1.06
Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq/11 activation and calcium mobilisation in CHO cells. Eur J Pharmacol (2008) 1.06
Differential activation of Gq/11 and Gi(3) proteins at 5-hydroxytryptamine(2C) receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol Pharmacol (2002) 1.05
Eating high fat chow enhances the locomotor-stimulating effects of cocaine in adolescent and adult female rats. Psychopharmacology (Berl) (2012) 1.02
Effect of early rearing conditions on alcohol drinking and 5-HT1A receptor function in C57BL/6J mice. Int J Neuropsychopharmacol (2006) 1.00
Insulin replacement restores the behavioral effects of quinpirole and raclopride in streptozotocin-treated rats. J Pharmacol Exp Ther (2006) 0.97
Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats. Neuropharmacology (2005) 0.97
Characterization of an mGluR2/3 negative allosteric modulator in rodent models of depression. J Neurogenet (2011) 0.97
S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: I. Receptor-binding profile and functional actions at G-protein-coupled receptors. J Pharmacol Exp Ther (2007) 0.94
Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice. Behav Pharmacol (2008) 0.92
Nociceptive spinal withdrawal reflexes but not spinal dorsal horn wide-dynamic range neuron activities are specifically inhibited by halothane anaesthesia in spinalized rats. Eur J Neurosci (2005) 0.92
Continuous administration of the 5-hydroxytryptamine1A agonist (3-Chloro-4-fluoro-phenyl)-[4-fluoro-4-[[(5-methyl-pyridin-2-ylmethyl) -amino]-methyl]piperidin-1-yl]-methadone (F 13640) attenuates allodynia-like behavior in a rat model of trigeminal neuropathic pain. J Pharmacol Exp Ther (2003) 0.91
F15599, a highly selective post-synaptic 5-HT(1A) receptor agonist: in-vivo profile in behavioural models of antidepressant and serotonergic activity. Int J Neuropsychopharmacol (2010) 0.91
5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function. Psychopharmacology (Berl) (2013) 0.91
Penile erection and yawning induced by dopamine D2-like receptor agonists in rats: influence of strain and contribution of dopamine D2, but not D3 and D4 receptors. Behav Pharmacol (2009) 0.91
Revisiting serotonin reuptake inhibitors and the therapeutic potential of "uptake-2" in psychiatric disorders. ACS Chem Neurosci (2013) 0.90
ADX71743, a potent and selective negative allosteric modulator of metabotropic glutamate receptor 7: in vitro and in vivo characterization. J Pharmacol Exp Ther (2012) 0.90
Pharmacological profiles in rats of novel antipsychotics with combined dopamine D2/serotonin 5-HT1A activity: comparison with typical and atypical conventional antipsychotics. Behav Pharmacol (2007) 0.90
Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties. Neuropsychopharmacology (2005) 0.90
Gender differences in the enhanced vulnerability of BDNF+/- mice to mild stress. Int J Neuropsychopharmacol (2009) 0.90
The five choice serial reaction time task: comparison between Sprague-Dawley and Long-Evans rats on acquisition of task, and sensitivity to phencyclidine. Pharmacol Biochem Behav (2009) 0.89
Characterization of phospholipase C activity at h5-HT2C compared with h5-HT2B receptors: influence of novel ligands upon membrane-bound levels of [3H]phosphatidylinositols. Naunyn Schmiedebergs Arch Pharmacol (2002) 0.89
Curative-like analgesia in a neuropathic pain model: parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist. Eur J Pharmacol (2007) 0.89
Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase. Eur J Pharmacol (2006) 0.89
Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain. J Pharmacol Exp Ther (2005) 0.89
Depletion of 5-HT disrupts prepulse inhibition in rats: dependence on the magnitude of depletion, and reversal by a 5-HT precursor. Neuropsychopharmacology (2002) 0.89
F15599, a preferential post-synaptic 5-HT1A receptor agonist: activity in models of cognition in comparison with reference 5-HT1A receptor agonists. Eur Neuropsychopharmacol (2010) 0.88
Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism? J Pharmacol Exp Ther (2011) 0.88
Acute and chronic effects of ramelteon in rhesus monkeys (Macaca mulatta): dependence liability studies. Behav Neurosci (2006) 0.88
Novel gamma-hydroxybutyric acid (GHB) analogs share some, but not all, of the behavioral effects of GHB and GABAB receptor agonists. J Pharmacol Exp Ther (2005) 0.88
Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade. Neuropsychopharmacology (2006) 0.88
High-efficacy 5-HT1A receptor activation causes a curative-like action on allodynia in rats with spinal cord injury. Eur J Pharmacol (2004) 0.88
Evidence for D2 receptor mediation of amphetamine-induced normalization of locomotion and dopamine transporter function in hypoinsulinemic rats. J Neurochem (2007) 0.87
Native rat hippocampal 5-HT1A receptors show constitutive activity. Mol Pharmacol (2006) 0.87
Effects of acute and subchronic administration of dexefaroxan, an alpha(2)-adrenoceptor antagonist, on memory performance in young adult and aged rodents. J Pharmacol Exp Ther (2002) 0.87
Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats. Eur J Pain (2004) 0.87
Relative stereochemical determination and synthesis of the C1-C17 fragment of a new natural polyketide. J Org Chem (2009) 0.87
Discriminative stimulus effects of GHB and GABA(B) agonists are differentially attenuated by CGP35348. Eur J Pharmacol (2006) 0.87
Neuroleptic-like effects of gamma-hydroxybutyrate: interactions with haloperidol and dizocilpine. Eur J Pharmacol (2004) 0.86
Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat. Neuropharmacology (2005) 0.86
Streptozotocin-induced diabetes differentially modifies haloperidol- and gamma-hydroxybutyric acid (GHB)-induced catalepsy. Eur J Pharmacol (2005) 0.86
5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol (2002) 0.86
Novel antipsychotics activate recombinant human and native rat serotonin 5-HT1A receptors: affinity, efficacy and potential implications for treatment of schizophrenia. Int J Neuropsychopharmacol (2005) 0.86
Antidepressant-like drug effects in juvenile and adolescent mice in the tail suspension test: Relationship with hippocampal serotonin and norepinephrine transporter expression and function. Front Pharmacol (2013) 0.85
Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release. Eur J Pharmacol (2006) 0.85
Differential effects of serotonin 5-HT1A receptor agonists on the discriminative stimulus effects of the 5-HT2A receptor agonist 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rats and rhesus monkeys. J Pharmacol Exp Ther (2010) 0.85
Optimization of the separation of Vinca alkaloids by nonaqueous capillary electrophoresis. J Chromatogr A (2002) 0.85
The PARP inhibitor benzamide protects against kainate and NMDA but not AMPA lesioning of the mouse striatum in vivo. Brain Res (2004) 0.85
[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging. Eur J Nucl Med Mol Imaging (2009) 0.85
Food restriction and streptozotocin differentially modify sensitivity to the hypothermic effects of direct- and indirect-acting serotonin receptor agonists in rats. Eur J Pharmacol (2009) 0.85
GABAB receptor-positive modulators: brain region-dependent effects. J Pharmacol Exp Ther (2011) 0.85
A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer's disease. CNS Neurosci Ther (2014) 0.84
The antipsychotics clozapine and olanzapine increase plasma glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur J Pharmacol (2008) 0.84
Interactions between Δ(9)-tetrahydrocannabinol and heroin: self-administration in rhesus monkeys. Behav Pharmacol (2012) 0.84
The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding. Eur J Pharmacol (2007) 0.84
WAY-100635 has high selectivity for serotonin 5-HT(1A) versus dopamine D(4) receptors. Eur J Pharmacol (2007) 0.84
Milnacipran is active in models of irritable bowel syndrome and abdominal visceral pain in rodents. Eur J Pharmacol (2011) 0.84
Differential agonist and inverse agonist profile of antipsychotics at D2L receptors coupled to GIRK potassium channels. Neuropharmacology (2007) 0.84
Effects of serotonin (5-HT)1A and 5-HT2A receptor agonists on schedule-controlled responding in rats: drug combination studies. Psychopharmacology (Berl) (2010) 0.83
Towards a new generation of potential antipsychotic agents combining D2 and 5-HT1A receptor activities. J Med Chem (2007) 0.83
Interactions of gamma-hydroxy butyrate with ethanol and NCS 382. Eur J Pharmacol (2003) 0.83
Anticataleptic properties of alpha2 adrenergic antagonists in the crossed leg position and bar tests: differential mediation by 5-HT1A receptor activation. Psychopharmacology (Berl) (2004) 0.83
Evaluation of milnacipran, in comparison with amitriptyline, on cold and mechanical allodynia in a rat model of neuropathic pain. Eur J Pharmacol (2011) 0.83
Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages. DNA Cell Biol (2004) 0.82
Comparison of the behavioral effects of gamma-hydroxybutyric acid (GHB) and its 4-methyl-substituted analog, gamma-hydroxyvaleric acid (GHV). Drug Alcohol Depend (2005) 0.82
Effects of gamma-hydroxybutyrate (GHB) on schedule-controlled responding in rats: role of GHB and GABAB receptors. J Pharmacol Exp Ther (2003) 0.82
Reduced effectiveness of escitalopram in the forced swimming test is associated with increased serotonin clearance rate in food-restricted rats. Int J Neuropsychopharmacol (2009) 0.82
Behavioral effects of amphetamine in streptozotocin-treated rats. Eur J Pharmacol (2007) 0.82
Effects of direct- and indirect-acting serotonin receptor agonists on the antinociceptive and discriminative stimulus effects of morphine in rhesus monkeys. Neuropsychopharmacology (2011) 0.82
Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane (DOM), ketanserin, and (R)-(+)-{alpha}-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-pipidinemethanol (MDL100907) in rats. J Pharmacol Exp Ther (2009) 0.82
Catecholamine/Serotonin interactions: systems thinking for brain function and disease. Adv Pharmacol (2013) 0.82
The central serotonin 2B receptor: a new pharmacological target to modulate the mesoaccumbens dopaminergic pathway activity. J Neurochem (2010) 0.82
In vivo occupancy of dopamine D2 receptors by antipsychotic drugs and novel compounds in the mouse striatum and olfactory tubercles. Naunyn Schmiedebergs Arch Pharmacol (2006) 0.82
Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation. Brain Res (2005) 0.81
The novel analgesic, F 13640, produces intra- and postoperative analgesia in a rat model of surgical pain. Eur J Pharmacol (2005) 0.81
S32212, a novel serotonin type 2C receptor inverse agonist/α2-adrenoceptor antagonist and potential antidepressant: I. A mechanistic characterization. J Pharmacol Exp Ther (2011) 0.81
The 5-HT(1A) receptor agonist F 13640 attenuates mechanical allodynia in a rat model of trigeminal neuropathic pain. Eur J Pharmacol (2002) 0.81
Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: detection of agonist and inverse agonist properties. Naunyn Schmiedebergs Arch Pharmacol (2007) 0.81
Monoamine metabolism and behavioral responses to ethanol in mitochondrial aldehyde dehydrogenase knockout mice. Alcohol Clin Exp Res (2006) 0.81
High-efficacy 5-HT1A agonists for antidepressant treatment: a renewed opportunity. J Med Chem (2007) 0.81
Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs. Curr Pharm Des (2015) 0.80